Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers assessed the effects of deferasirox in 85 children with ß-thalassemia in Kirkuk and reported that while 55.3% experienced a reduction in serum ferritin, 9.4% had adverse effects, indicating that deferasirox is generally well-tolerated as an iron chelator with modifiable side effects.

Apremilast may help treat hair loss in alopecia areata.

This study suggests that HDAC inhibitors, such as Vorinostat and Entinostat, could be effective in promoting hair regrowth in a mouse model of alopecia areata.

This commentary highlights the consistency of recent findings on low-dose oral minoxidil's tolerability for androgenetic alopecia, noting infrequent side effects except for hypertrichosis.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

The study found that IPI-926 was well tolerated up to 160 mg once daily for 28-day cycles and showed activity as a single-agent treatment in Hedgehog pathway inhibitor-naïve patients with basal cell carcinoma.

This review found no evidence supporting the efficacy of methotrexate for inducing remission in active ulcerative colitis compared to placebo or active comparators.

This study found that prophylactically administering amotosalen-treated allogeneic donor T cells at transplantation significantly improved immune reconstitution and protection against murine cytomegalovirus infection without inducing graft-versus-host disease.

In this report, a 25-year-old female patient with anti-MDA5 antibody-positive dermatomyositis and alopecia areata achieved complete remission of hair loss after treatment with baricitinib.

This meta-analysis reports that ritlecitinib significantly improved hair growth in alopecia areata patients compared to placebo, although its potential requires further clinical exploration.

This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.

The authors concluded that pegylated liposomal doxorubicin may offer comparable efficacy to conventional doxorubicin with reduced toxicity in metastatic breast cancer treatment.

This study, using modified Delphi panels, provided consensus recommendations for managing alpelisib-induced hyperglycemia and rash, advising prophylactic metformin starting for certain risk groups and the use of nonsedating H1 antihistamines and topical steroids for initial rash management.

Adding diltiazem to a beta blocker can cause dangerously slow heart rates.

This case report observed successful hair regrowth with ritlecitinib in a patient with severe alopecia who did not respond to a previous year of baricitinib therapy.

In this study, researchers isolated new compounds from the plant *Calanthe cardioglossa* and found that five of these compounds, particularly calancardin B, significantly reduced TNF-α levels in immune cells relevant to multiple sclerosis, suggesting potential for immunomodulatory effects.

This case report highlights a 33-year-old female with systemic lupus erythematosus and refractory alopecia who experienced significant hair regrowth after treatment with tofacitinib, maintained even after glucocorticoid tapering over two years.

This article discusses the interest in folic acid antagonists for leukemia treatment, noting their potential mechanism of interfering with cellular growth, but reports no new clinical results.

This case study reports a 15-year-old girl from a visceral leishmaniasis-endemic area in Greece presenting with various symptoms, including high fever, morning joint pain, and blood in urine, eventually leading to findings like rash, anemia, and kidney issues. Results are not detailed in this abstract.

This study, involving patients with early rheumatoid arthritis, found that treatment regimens combining methotrexate and glucocorticoids, with or without initial high-dose methylprednisolone, showed higher remission rates over one year compared to methotrexate or leflunomide alone, and all regimens were generally well-tolerated.

In this case report, a 59-year-old man experienced recurrent pericardial effusion linked to minoxidil, with serologic indications of drug-induced lupus erythematosus, underscoring the need for clinicians to consider this rare complication of widespread minoxidil use.

Albendazole can cause hair loss, and piroxicam can cause fixed drug eruption.

This study found that letrozole, an aromatase inhibitor, reduced the incidence and severity of PTZ-induced kindling seizures in mice, potentially due to its effects on 17β-estradiol and neurosteroid synthesis.

In this case report, a 55-year-old woman developed alopecia areata approximately one year into her treatment with upadacitinib for atopic dermatitis, raising questions about a potential drug-induced link that has not been reported before.

This study found that the evodiamine derivative 2-16 exhibited the highest antitumor activity and a broad spectrum of activity against various human cancer cell lines, with improved solubility.

This study discusses levetiracetam's role as an alternative treatment for idiopathic generalized epilepsies, highlighting its potential effectiveness, especially for patients unsuitable for valproate.

In this study, low-dose oral minoxidil for androgenetic alopecia was generally safe, showing small average changes in blood pressure and heart rate with infrequent cardiovascular issues, though monitoring is essential, especially in patients with conditions like hypertension or arrhythmias.

This study found that sodium valproate significantly reduced seizure frequency by over 50% in about 70% of patients with generalized seizures but was less effective for partial seizures.